Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
REPL Replimune Group Inc
- Stocks
- Healthcare
- NASDAQ: REPL
Price (delayed)
$9.69
Market cap
$746.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$710.31M
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary
Highlights
The company's EPS rose by 5% YoY
The company's equity fell by 14% QoQ but it rose by 11% YoY
Replimune Group's quick ratio has decreased by 31% from the previous quarter and by 26% YoY
The net income has contracted by 15% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of REPL
Market
Valuations
Earnings
Shares outstanding
77.09M
Market cap
$746.97M
Enterprise value
$710.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$261.63M
Net income
-$247.3M
EBIT
-$238.94M
EBITDA
-$235.43M
Free cash flow
-$198.94M
Per share
Balance sheet
Liquidity
EPS
-$3.07
EPS diluted
-$3.07
Free cash flow per share
-$2.47
Book value per share
$5.4
Revenue per share
$0
TBVPS
$6.84
Total assets
$551.33M
Total liabilities
$135.49M
Debt
$76.17M
Equity
$415.84M
Working capital
$433.52M
Debt to equity
0.18
Current ratio
7.95
Quick ratio
7.85
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.2%
Return on equity
-58%
Return on invested capital
-54.7%
Return on capital employed
-48.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REPL stock price
How has the Replimune Group stock price performed over time
Intraday
0.62%
1 week
14.95%
1 month
-3.2%
1 year
91.12%
YTD
-19.98%
QTD
-0.62%
Financial performance
How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$261.63M
Net income
-$247.3M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 15% YoY and by 8% from the previous quarter
The operating income has declined by 11% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does REPL's price correlate with its fundamentals
Growth
What is Replimune Group's growth rate over time
Valuation
What is Replimune Group stock price valuation
P/E
N/A
P/B
1.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 5% YoY
REPL's price to book (P/B) is 26% lower than its 5-year quarterly average of 2.4 but 4.7% higher than its last 4 quarters average of 1.7
The company's equity fell by 14% QoQ but it rose by 11% YoY
Efficiency
How efficient is Replimune Group business performance
Replimune Group's return on invested capital has decreased by 28% YoY and by 8% QoQ
REPL's ROE is down by 19% YoY and by 6% QoQ
Replimune Group's return on assets has decreased by 14% YoY and by 5% QoQ
Dividends
What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REPL.
Financial health
How did Replimune Group financials performed over time
Replimune Group's quick ratio has decreased by 31% from the previous quarter and by 26% YoY
REPL's current ratio is down by 30% QoQ and by 26% YoY
Replimune Group's debt is 82% less than its equity
The company's equity fell by 14% QoQ but it rose by 11% YoY
The debt to equity has increased by 13% since the previous quarter but it has declined by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.